title: Response to nab-paclitaxel and nedaplatin in a heavily-metastatic thymic carcinoma: A case report.
abstract: Metastatic thymic carcinoma is an aggressive cancer that usually responds poorly to multimodal therapies. Although surgical resection is the preferred treatment for patients with advanced or metastatic disease, the clinical prognosis is typically poor. The present study describes a 63-year-old patient with thymic carcinoma who underwent a range of antitumor treatments, including surgical resection, post-operative radiotherapy and post-operative chemotherapy with several drugs, but ultimately responded to treatment with nab-paclitaxel (nab-P) and nedaplatin. Subsequent to six cycles of nab-P and nedaplatin, the lung and peritoneal metastases decreased in size and the pleural effusion was reduced. To the best of our knowledge, this is the first study to describe the response of an advanced thymic carcinoma to nab-P chemotherapy.
authors: Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu, P.R. China ; Nanjing Clinical Center of Respiratory Diseases, Nanjing, Jiangsu, P.R. China.
authors: Ping
authors: P
authors: Zhan
authors: Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu, P.R. China ; Nanjing Clinical Center of Respiratory Diseases, Nanjing, Jiangsu, P.R. China.
authors: Haiyan
authors: H
authors: Xie
authors: Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu, P.R. China ; Nanjing Clinical Center of Respiratory Diseases, Nanjing, Jiangsu, P.R. China.
authors: Li-Ke
authors: LK
authors: Yu
keywords: chemotherapy; molecular target therapy; nab-paclitaxel; thymic carcinoma